Nucl Med Mol Imaging.
2010 Dec;44(4):233-240.
68Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography
- Affiliations
-
- 1Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine, 101 Daehangno Jongno-gu, Seoul 110-744, South Korea. jmjng@snu.ac.kr
Abstract
- 68Ga is a promising emerging radionuclide for positron emission tomography (PET). It is produced using a 68Ge/68Ga-generator, and thus, would enable the cyclotron-independent distribution of PET. However, new 68Ga-labeled radiopharmaceuticals that can replace 18F-labeled agents like [18F]fluorodeoxyglucose (FDG) are needed. Most of the 68Ga-labeled derivatives currently used are peptide agents, but the developments of other agents, such as amino acid derivatives, nitroimidazole derivatives, and glycosylated human serum albumin, are being actively pursued in many laboratories. Thus, appearance of new 68Ga-labeled radiopharmaceuticals with high impact are expected in the near future. Here, we present an overview of 68Ga-labeled agents in terms of their clinical significances and relevances to the management of certain tumors, and pertinent pre-clinical developments.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Evaluation of Myocardial Blood Flow and Coronary Flow Reserve Using Positron Emission Tomography
- Radiolabeled Phosphonium Salts as Mitochondrial Voltage Sensors for Positron Emission Tomography Myocardial Imaging Agents
- Emerging Tracers for Nuclear Cardiac PET Imaging
- Measuring tumor metabolic heterogeneity on positron emission tomography: utility in cervical cancer
- Diagnostic Value of 68Ga-DOTATATE PET/CT in Liver Metastases of Neuroendocrine Tumours of Unknown Origin
